Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.
Stanley L CohanKeith EdwardsLindsay LucasTiffany Gervasi-FollmarJudy O'ConnorJessica SiutaVineetha KamathLore GartenChiayi ChenJames ThomasKyle SmootKiren Kresa-ReahlKateri J SpinelliPublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clinically stable patients off natalizumab to another therapy.ClinicalTrials.gov Identifier: NCT01970410.
Keyphrases
- multiple sclerosis
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- white matter
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- stem cells
- palliative care
- cell therapy
- patient reported outcomes
- replacement therapy